Taiwan's First Biosimilar - Modeled After Amgen Drug - Set For Phase III Trials By Year's End
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Taiwan's first biosimilar drug is one step closer to market, with Phase III clinical trials set to start in South Korea before the end of the year